Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stereotactic Ablative Radiotherapy for Oligoprogressive Metastatic Castration-Resistant Prostate Cancer During Abiraterone Therapy

NCT04838899 is registered in ClinicalTrials.gov with Sunnybrook Health Sciences Centre as lead sponsor.

NCT NCT04838899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04838899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stereotactic Ablative Radiotherapy for Oligoprogressive Metastatic Castration-Resistant Prostate Cancer During Abiraterone Therapy
Lead sponsor
Sunnybrook Health Sciences Centre
Phase
Not applicable
Overall status
Recruiting
Start date
July 16, 2016
Completion date
December 31, 2026
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer, oligoprogressive